Viracta Therapeutics, Inc.

OTCPK:VIRX Stock Report

Market Cap: US$377.6k

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Viracta Therapeutics Management

Management criteria checks 0/4

We currently do not have sufficient information about the CEO.

Key information

Craig Jalbert

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenureless than a year
CEO ownershipn/a
Management average tenureno data
Board average tenureno data

Recent management updates

Recent updates

Seeking Alpha • Sep 19

Viracta Therapeutics names Mark Rothera as new CEO

Viracta Therapeutics (NASDAQ:VIRX) on Monday appointed Mark Rothera as its president and CEO, succeeding Ivor Royston. Royston will continue to serve as a member of VIRX's board, the company said in a statement. VIRX said Rothera had more than 30 years of experience in the biopharmaceutical industry. Prior to joining VIRX, Rothera was CEO of Silence Therapeutics (SLN). He also previously served as the top boss at Orchard Therapeutics (ORTX). VIRX stock -4.2% to $5.45 in premarket trading.
Seeking Alpha • Sep 07

Viracta Therapeutics gets European orphan drug designation for lymphoma combo treatment

Viracta Therapeutics (NASDAQ:VIRX) on Wednesday said the European Commission had granted an orphan drug designation to its all-oral combination product candidate Nana-val for the treatment of peripheral T-cell lymphoma. The company said this was its first such designation granted in Europe and the fifth globally. Nana-val is a combination of the company's inhibitor nanatinostat and antiviral agent valganciclovir. The U.S. FDA had previously granted Nana-val an orphan drug designation for the treatment of T-cell lymphoma and a few other indications, VIRX said. The orphan drug designation by the European Commission was based on a positive opinion given by the European drug regulator's human medicines committee. VIRX stock -4.9% to $4.09 in early trading.
Seeking Alpha • Aug 09

Viracta Therapeutics GAAP EPS of -$0.28

Viracta Therapeutics press release (NASDAQ:VIRX): Q2 GAAP EPS of -$0.28. Cash, cash equivalents and short-term investments totaled approximately $83.1 million

CEO

Craig Jalbert (63 yo)

less than a year
Tenure

Mr. Craig R. Jalbert, CIRA is CEO, President, Corporate Treasurer, Corporate Secretary & Director of T2 Biosystems, Inc. from April 3, 2025. He is CEO, President, CFO, Treasurer, Corporate Secretary & Dire...

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/07/18 02:32
End of Day Share Price 2025/07/16 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Viracta Therapeutics, Inc. is covered by 2 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Andrew BerensLeerink Partners LLC
Hartaj SinghOppenheimer & Co. Inc.